Active, not recruitingPhase 3NCT05057494

A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Studying B-cell chronic lymphocytic leukemia

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: AstraZeneca
Intervention: Acalabrutinib(drug)
Enrollment: 607 target
Eligibility: 18-130 years · All sexes
Timeline: 2022 – 2029

Study locations (30)

Research Site, Tucson, Arizona, United States
Research Site, La Jolla, California, United States
Research Site, Longmont, Colorado, United States
Research Site, Jacksonville, Florida, United States
Research Site, Boston, Massachusetts, United States
Research Site, St Louis, Missouri, United States
Research Site, Buffalo, New York, United States
Research Site, New Hyde Park, New York, United States
Research Site, New York, New York, United States
Research Site, Rochester, New York, United States
Research Site, Charlotte, North Carolina, United States
Research Site, Cleveland, Ohio, United States
Research Site, Eugene, Oregon, United States
Research Site, Philadelphia, Pennsylvania, United States
Research Site, Nashville, Tennessee, United States
+15 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05057494 on ClinicalTrials.gov

Other trials for B-cell chronic lymphocytic leukemia

Additional recruiting or active studies for the same condition.

See all trials for B-cell chronic lymphocytic leukemia →

← Back to all trials